Recent studies show that patients with the most serious forms of the coronavirus had high levels of IL-6, a common inflammatory cytokine, which MediSieve has previously encountered while researching sepsis and cytokine storms.

Finding a way to selectively and rapidly target and remove IL-6 from COVID-19 patients’ bloodstream could be extremely beneficial.

Currently, the majority of severe COVID-19 patients are treated with immunoblockers or immunosuppressants. While still effective treatments, their most dangerous drawback is that the suppressants stay in the bloodstream, leaving patients immunsupressed while fighting the infection.

Broad risk groups

Immune deficient Inpatients

Pregnant

Over 70s

Significant worldwide burden

26m confirmed cases
850k deaths

High morbidity

Respiratory distress

Sepsis

Long patient care

Second wave threat

120k hospital deaths
estimated in the UK

By focusing specifically on IL-6 MediSieve can rapidly bring a product to market to alleviate the cytokine storm and hyperimmune reaction as well as the secondary sepsis that is the cause of significant mortality in COVID-19 patients. In vitro data suggest that adult IL-6 levels could be reduced by 80% in 4 hours.

Latest News

MediSieve Announces Positive Final Results from Phase 1 Clinical Trial of its Magnetic Blood Filtration Platform

MediSieve Announces Positive Final Results from Phase 1 Clinical Trial of its Magnetic Blood Filtration Platform
December 07, 2022

Magnetic Blood Filtration Platform shown to be safe and well tolerated, with no serious adverse events. Investigators recommend further development of the Platform, which has a range of potential clinical applications in inflammation, oncology, gene therapies and others. ...
MediSieve Announces First Volunteer Successfully Enrolled in Phase 1 Clinical Study

MediSieve Announces First Volunteer Successfully Enrolled in Phase 1 Clinical Study
July 08, 2022

Radboud University Medical Center is Conducting Safety Evaluation of MediSieve’s Magnetic Haemofiltration System for the Treatment of Acute Hyperinflammation.